Hoisnard L, Pina Vegas L, Dray-Spira R, et al. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis 2023;82:182-8. doi:10.1136/ard-2022-222824

In discussion on page 187, the following sentence does not contain the final results: "Our results for subgroups of patients with at least one cardiovascular risk who were 50 years old or older and 65 years old or older were not significant for risk of both MACEs and VTEs with a JAKi compared with the TNFi adalimumab: HRw 2.1 (0.6 to 7.8) and 2.2 (0.4 to 12.5) and 1.1 (0.5 to 2.2) and 0.8 (0.4 to 2.0), respectively.” This should read: "Our results for subgroups of patients with at least one cardiovascular risk who were 50 years old or older and 65 years old or older were not significant for risk of both MACEs and VTEs with a JAKi compared with the TNFi adalimumab: HRw 1.0 (0.6 to 1.9) and 0.7 (0.4 to 1.3) and 1.5 (0.8 to 2.6) and 1.2 (0.6 to 2.3), respectively.”